International Longevity Day will see scientists, advocates and citizens carry the geroscience debate from medicine to Madrid City Hall.
Madrid will host a public march for longevity on 1 October – part protest, part pilgrimage, part scientific conference spilling out onto the pavement. Scientists, physicians, advocates and members of the public will walk together as part of the International Longevity Summit 2026, taking an argument usually confined to lecture halls out into the street instead.
The march, organized by the International Longevity Alliance (ILA), begins at the Royal National Academy of Medicine of Spain and threads through Puerta del Sol and the Congress of Deputies before finishing at Madrid City Hall. At four stops along the way, participants will read sections of the Madrid Longevity Declaration aloud; its central demand is straightforward enough – greater recognition of aging as a target for medical intervention, and more funding to back the science that might justify it.
Longevity.Technology: Longevity has spent much of its modern history talking to itself – at conferences, in laboratories and increasingly in investment rooms. Taking the argument onto Madrid’s streets is therefore more than a change of scenery; the march quite literally traces a route from medicine towards government, with the Madrid Longevity Declaration being read along the way. If geroscience is to influence research priorities, preventive healthcare and public policy, its case ultimately has to make sense beyond the already converted – particularly as longer lives force societies to confront not simply how many years people accumulate, but how many of them are spent in reasonable health. Public advocacy can help shift that conversation, although slogans such as “STOP Aging” inevitably flatten a field whose biology is anything but simple. A march cannot supply the evidence, of course, nor settle the considerable scientific debate over whether aging itself should be treated as a condition; but it can ask a rather public question about what we choose to do as the evidence develops. For a movement accustomed to discussing longevity behind conference doors, taking a few thousand steps outside them may be no bad thing.
From academy to city hall
International Longevity Day was established by the ILA in 2013 to coincide with the UN’s International Day of Older Persons. Since then, advocates in countries including Italy, Germany, Brazil, Pakistan and Canada have used 1 October for talks, petitions and public demonstrations promoting research into extending healthy human life.
The Madrid event deliberately puts that advocacy in public view. Its starting point, the Royal National Academy of Medicine, is also hosting the International Longevity Summit on 30 September and 1 October; from there, marchers will move past regional and national political institutions before arriving at the Palacio de Cibeles.
“This will be the largest public march for longevity in history,” said José Cordeiro, chair of the Summit’s Organizing Committee. “But it is also just the beginning.”
Cordeiro argues that the purpose is not simply to celebrate increasing lifespan, but to focus attention on diseases associated with later life. “We are not marching to celebrate old age as it stands today. We are marching to end the diseases that make old age something to dread,” he said.
Why Madrid
There is some demographic neatness to the choice of venue. Eurostat data cited by organizers put life expectancy at birth in the Community of Madrid at 85.7 years in 2024, up from 84.3 years in 2014; Spain itself sits among Europe’s longest-lived populations.
Longevity, however, increasingly concerns the quality rather than merely the arithmetic of those additional years. Longer lifespan accompanied by prolonged multimorbidity and frailty presents a very different societal proposition from longer healthspan – and explains why prevention, aging biology and healthy longevity are moving further into conversations about healthcare systems and public policy.
A public experiment
Whether longevity advocacy can grow into a genuine public movement is still an open question. Scientific conferences have spent years building a vocabulary of hallmarks, biomarkers and interventions – a fluency few citizens have any obligation to share.
Madrid will test what happens when some of those ideas leave the lecture hall. The science will still need to make its own case – but on 1 October, at least, the conversation will have a considerably larger room.
